LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
NBTX
Nanobiotix S.A.
There isn't enough reported data to score NBTX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
NBTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NBTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
NBTX PE Valuation
NBTX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
NBTX Forward outlook
There aren't enough analyst estimates for NBTX to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over NBTX in the latest year-over-year earnings comparison.
NBTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2024 | -$0.82 | +$1.05 |
| Q4 2023 | -$1.20 | +$0.62 |
| Q2 2023 | -$1.87 | -$0.50 |
| Q4 2022 | -$1.82 | -$0.32 |
NBTX lost $0.56 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over NBTX in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over NBTX on profitability, with a higher operating margin.
NBTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $6.2M | -79% |
| Q2 2025 | $29.6M | +187% |
| Q2 2024 | $10.3M | +182% |
| Q4 2023 | $36.6M | +855% |
| Q2 2023 | $3.7M | +148% |
| Q4 2022 | $3.8M | +160% |
| Q2 2022 | $1.5M | +0.8% |
| Q4 2021 | $1.5M | +51% |
NBTX's revenue has slid since its 2023 peak: $6M last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -323% | -68 points |
| Q4 2025 | -195% | -191 points |
| Q2 2025 | 3% | +773 points |
| Q2 2024 | -255% | +1693 points |
| Q4 2023 | -4.3% | +1713 points |
| Q2 2023 | -770% | +1487 points |
| Q4 2022 | -604% | +1453 points |
| Q2 2022 | -1947% | -678 points |
NBTX's operating margin was −323% last quarter, down 319 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
NBTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$25.5M | -$6M |
| Q4 2025 | -$18.2M | -$2.6M |
| Q2 2025 | -$19.5M | -$12.5M |
| Q4 2024 | -$15.6M | -394% |
| Q2 2024 | -$7M | +$12.5M |
| Q4 2023 | $5.3M | +$27.1M |
| Q2 2023 | -$19.5M | -$1.1K |
| Q4 2022 | -$21.8M | -$5.1M |
NBTX has burned cash in almost every quarter: −$79M over the past year, against −$43M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over NBTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
NBTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +1.5M shares |
| 1 year | +116% | +26.3M shares |
| 3 years | +227% | +33.9M shares |
NBTX has 49M diluted shares, up 116% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2024 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
NBTX Net Leverage
NBTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
NBTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.4 | Neutral |
| Stochastic | 41.2 | Neutral |
NBTX's weekly RSI is 49 (neutral) and its Stochastic is 41 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
NBTX PE vs Healthcare Sector
NBTX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over NBTX on trend strength, trading above more of its moving averages.
NBTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.5 | 13% above |
| 20 week MA | $34.6 | 6.8% below |
| 50 week MA | $32.0 | 0.7% above |
| 100 week MA | $20.0 | 61% above |
| 200 week MA | $12.9 | 150% above |
NBTX's trend is mixed: it's above four of its five weekly moving averages, and 150% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
NBTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.0 | $17.2 | +1.5% |
| 2021 | $17.2 | $7.87 | -54% |
| 2022 | $7.87 | $4.00 | -49% |
| 2023 | $4.00 | $7.28 | +82% |
| 2024 | $7.28 | $3.00 | -59% |
| 2025 | $3.00 | $23.0 | +668% |
| 2026 YTD | $23.0 | $32.3 | +40% |
NBTX has the edge over LLY on returns for 2026, with the stronger performance.